First deputy director for research at the Central Research Institute of Epidemiology under the consumer rights watchdog Rospotrebnadzor, associate member of the Academy of Sciences Alexander Gorelov, believes that there are sufficient reasons for nominate the scientists who have developed vaccines against the novel coronavirus for a Nobel Award.
“The vaccine developers should be nominated for the Nobel Award. I believe there are sufficient reasons for this,” he said at a round-table discussion entitled Russian Science and Medicine vs COVID-19. Challenges and Achievements.
Gorelov said that currently there were no alternatives to pre-emptive vaccination and all countries sought to achieve collective immunity, preferably post-vaccination immunity, and not acquired in the natural way.
“It goes without saying that no country around the world can say it has such a diversity of vaccines as Russia: from classical, developed by the Chumakov Center, to innovative, vector vaccines from the Gamaleya Center and the synthetic polypeptide one developed by Vektor,” he said.
“Medics have the right to choose what vaccine should be recommended for a specific patient in accordance with the person’s individual features.
On August 11, 2020 Russia was the first to have registered a vaccine against the novel coronavirus, Sputnik V, from the Gamaleya research center under the Health Ministry.
Later there followed the registration of another domestic vaccine, created by the center Vektor, of the national consumer rights watchdog Rospotrebnadzor. Very soon the registration of a third vaccine is due. It was developed by the Chumakov Center for Research into and Development of Immune and Biological Products.
The publication of the third clinical trial stage results for Russia’s Sputnik V COVID-19 vaccine in The Lancet, a reputable medical journal, proves that the jab is effective in countering the global pandemic, World Health Organization (WHO) representative to Russia Melita Vujnovic said Wednesday in an interview with Russian TV.
“We welcome the publication, it speaks well about the vaccine efficacy,” she said.
The WHO envoy added that people from high-risk group should be vaccinated first to bring down the mortality rate. She also underlined that it is vital to procure vaccine doses to countries that have no resources to purchase them. “The WHO is actively involved. Talks are underway with all countries at the highest level, we expect support from Russia as well to provide the vaccine to everyone who needs it,” Vujnovic underlined.
The Lancet published the article reviewing results of the third stage of Sputnik V’s clinical trials on Tuesday.
The article notes the highly positive performance of the jab, putting it among the most safe and efficient in the world. The shot efficacy stands at 91.6%, while the result for those aged over 60 is even higher, 91.8% Moreover, 98% of all volunteers who had the Russian vaccine had the antibody response.
Header: Production of ‘Medgamal’ two components COVID-19 vaccine, developed by the Gamaleya National Research Centre for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) at the Gamaleya National Research Centre in Moscow, Russia, August 6, 2020.